Teriparatide Ambio Pharma: Uses, Dosage & Side Effects
A biosimilar recombinant parathyroid hormone (1-34) anabolic therapy for severe osteoporosis, supplied as a 20 microgram/80 microliter solution in a pre-filled injection pen
Teriparatide Ambio Pharma is a biosimilar medicine containing teriparatide, a recombinant form of the first 34 amino acids of human parathyroid hormone (rhPTH 1-34). It is the active, biologically essential fragment of natural parathyroid hormone and is used to treat severe osteoporosis in postmenopausal women, men at increased risk of fracture, and adults with osteoporosis caused by long-term use of corticosteroids. Unlike antiresorptive drugs such as bisphosphonates or denosumab that slow bone breakdown, teriparatide is an anabolic therapy that actively stimulates the formation of new bone. Teriparatide Ambio Pharma is supplied as a pre-filled multi-dose pen delivering 20 micrograms once daily by subcutaneous injection and has been shown to significantly increase bone mineral density and reduce the risk of vertebral and non-vertebral fractures.
Quick Facts: Teriparatide Ambio Pharma
Key Takeaways
- Teriparatide Ambio Pharma is a biosimilar containing the recombinant 1-34 fragment of human parathyroid hormone; it is the only widely used anabolic osteoporosis therapy (along with abaloparatide and romosozumab) and preferentially stimulates osteoblasts to build new bone.
- It is indicated for severe osteoporosis in postmenopausal women and men at high risk of fracture, and for osteoporosis caused by long-term systemic glucocorticoid therapy (e.g., prednisone equivalents greater than 5 mg/day for more than 3 months).
- Treatment is given as a once-daily 20 microgram subcutaneous injection using a pre-filled multi-dose pen; the maximum lifetime duration is 24 months, after which patients must switch to an antiresorptive drug to preserve gains.
- Contraindications include pre-existing hypercalcemia, severe kidney impairment, Paget’s disease of bone, unexplained elevations of alkaline phosphatase, prior skeletal radiation, skeletal malignancy or bone metastases, pregnancy, and breastfeeding.
- In the pivotal Fracture Prevention Trial, teriparatide reduced new vertebral fractures by approximately 65% and non-vertebral fragility fractures by about 53% compared with placebo over a median 19-month treatment period.
What Is Teriparatide Ambio Pharma and What Is It Used For?
Teriparatide Ambio Pharma contains the active substance teriparatide, a recombinant polypeptide consisting of the first 34 amino acids of human parathyroid hormone (hPTH 1-34). This N-terminal fragment retains the full biological activity of the complete 84-amino-acid parathyroid hormone molecule. The medicine is manufactured using recombinant DNA technology in genetically modified Escherichia coli bacteria and is identical in amino-acid sequence to the reference product Forsteo (marketed as Forteo in the United States), which was first authorized in the early 2000s by Eli Lilly.
As a biosimilar, Teriparatide Ambio Pharma has been shown through rigorous head-to-head comparative studies to be highly similar to its reference medicine in terms of quality, efficacy, safety and immunogenicity. Regulators such as the European Medicines Agency (EMA) only authorize biosimilars when the sponsor demonstrates that any minor structural differences do not affect clinical outcomes. Biosimilars are not generics: biological medicines are too complex to copy exactly, but biosimilar approval guarantees the medicine can be used interchangeably for all the indications of the reference product.
Teriparatide Ambio Pharma is approved for the treatment of osteoporosis. Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and deterioration of the microarchitecture of bone tissue, leading to bone fragility and a markedly increased risk of fracture. It is most common in postmenopausal women due to the accelerated bone loss that follows the decline in oestrogen, but men also develop osteoporosis, and both sexes can develop it as a consequence of long-term corticosteroid therapy, hormonal imbalances, or other chronic illnesses. According to the World Health Organization (WHO), osteoporotic fractures affect one in three women and one in five men over the age of 50 worldwide, making it a major public-health challenge.
The specific indications for teriparatide, harmonized across the EMA, FDA and other major regulators, are:
- Treatment of osteoporosis in postmenopausal women at high risk of fracture – including women with established osteoporosis who have had a previous osteoporotic fracture and/or multiple risk factors (low bone mineral density, advanced age, low body weight, long-term steroid use, or previous fracture history). Teriparatide significantly reduces the incidence of new vertebral and non-vertebral fractures in this group.
- Treatment of osteoporosis in men at increased risk of fracture – particularly those with primary (age-related) or secondary (e.g., hypogonadal) osteoporosis who have a history of fragility fracture or who have failed, not tolerated, or are not candidates for antiresorptive therapy.
- Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy – in women and men at increased risk of fracture who are taking corticosteroids (for example for rheumatoid arthritis, polymyalgia rheumatica, inflammatory bowel disease, lupus, or after organ transplantation). In randomized trials, teriparatide produced greater increases in bone mineral density and fewer new vertebral fractures than alendronate in glucocorticoid-induced osteoporosis.
How does teriparatide actually work? Parathyroid hormone is a peptide hormone produced naturally by the parathyroid glands and is the body’s principal regulator of calcium and bone metabolism. Continuous exposure to high PTH levels – as occurs in untreated primary or secondary hyperparathyroidism – leads to excessive bone resorption and loss of bone mass. Paradoxically, however, intermittent exposure produces the opposite effect: when PTH is administered as a once-daily injection, the transient rise in hormone activity stimulates osteoblasts (bone-forming cells) more than osteoclasts (bone-resorbing cells), creating a window during which new bone formation exceeds bone breakdown. This principle, known as the “anabolic window”, is the foundation of teriparatide therapy.
At a cellular level, teriparatide binds to the PTH type 1 receptor (PTH1R) on osteoblasts and osteocytes, activating cyclic AMP and other intracellular signalling pathways. The result is an increase in the number and activity of osteoblasts, a reduction in osteoblast apoptosis (programmed cell death), and enhanced bone modelling (deposition of new bone on existing surfaces) and remodelling (coupled resorption and formation). Over months of treatment, this leads to measurable increases in bone mineral density (typically 8–14% in the lumbar spine over 18–24 months), improvements in trabecular connectivity and cortical thickness, and most importantly, a substantial reduction in fracture risk.
Most osteoporosis drugs – bisphosphonates (alendronate, risedronate, zoledronate), denosumab, and selective estrogen receptor modulators – are antiresorptive agents. They slow the rate at which bone is broken down but do not build meaningful amounts of new bone. Teriparatide is anabolic: it actively increases bone formation. This makes it particularly valuable for patients who have already sustained fractures, who have very low bone density, or who continue to lose bone despite antiresorptive therapy. Because bone density gains can be lost when treatment stops, teriparatide should always be followed by an antiresorptive agent.
What Should You Know Before Using Teriparatide Ambio Pharma?
Contraindications
There are strict contraindications that must be reviewed before starting teriparatide. Your doctor will usually perform blood tests (calcium, alkaline phosphatase, creatinine) and a clinical assessment before prescribing this medicine.
- Hypersensitivity: Do not use if you are allergic to teriparatide or to any of the excipients in the pen (glacial acetic acid, sodium acetate trihydrate, mannitol, metacresol, water for injections, or hydrochloric acid/sodium hydroxide for pH adjustment).
- Pre-existing hypercalcemia: Teriparatide transiently increases serum calcium. It is contraindicated in anyone with baseline hypercalcemia, including patients with primary hyperparathyroidism.
- Severe renal impairment: Teriparatide must not be used in patients with severe kidney failure (estimated glomerular filtration rate below approximately 30 mL/min/1.73 m²). It may be used with caution in moderate renal impairment.
- Metabolic bone diseases other than primary osteoporosis: Including Paget’s disease of bone, hyperparathyroidism, and osteomalacia. These conditions fundamentally alter bone turnover and carry different risks with PTH analogs.
- Unexplained elevations of alkaline phosphatase: Unexplained increases in bone-specific alkaline phosphatase may indicate Paget’s disease, bone metastases or another bone disorder that must be evaluated before treatment.
- Prior external beam or implant radiation therapy to the skeleton: Radiation may predispose the skeleton to osteosarcoma; patients with a history of skeletal radiation must not receive teriparatide.
- Skeletal malignancy or bone metastases: Patients with active bone cancer or metastatic disease affecting bone must not use teriparatide.
- Pregnancy and breastfeeding: Teriparatide is contraindicated during pregnancy and lactation (see section below).
Warnings and Precautions
Studies in young growing rats showed a dose-dependent increase in osteosarcoma (a malignant bone tumor) with long-term high-dose teriparatide. This finding led to a boxed warning in the US prescribing information and to the 24-month lifetime treatment limit. Extensive post-marketing surveillance in humans has not demonstrated a causal link, and the overall osteosarcoma incidence in treated patients appears similar to background rates. Nonetheless, patients with increased baseline risk of osteosarcoma – including those with Paget’s disease, unexplained alkaline phosphatase elevations, open epiphyses (children/adolescents), or prior skeletal radiation – must not use teriparatide.
Before and during treatment, tell your doctor if any of the following apply to you:
- History of kidney stones (nephrolithiasis): Teriparatide can cause a modest increase in urinary calcium excretion (hypercalciuria), which could theoretically worsen the tendency to form calcium-containing stones. Patients with active urolithiasis or a recent history of stones should be treated with caution.
- Orthostatic hypotension: Transient orthostatic hypotension (a drop in blood pressure on standing) has been reported with the first few doses, typically within 4 hours of injection. It usually resolves within minutes to a few hours. Patients should administer the first few doses in circumstances where they can sit or lie down if they feel light-headed.
- Cardiac conditions: Transient increases in heart rate (tachycardia) have been observed after injection in some patients. If you have pre-existing arrhythmias, congestive heart failure, or known coronary artery disease, tell your doctor.
- Active or recent urolithiasis: If you have ongoing kidney stone disease, the small increases in urine calcium caused by teriparatide may worsen symptoms.
- Digoxin therapy: Teriparatide causes a transient rise in serum calcium that could, in theory, increase the risk of digoxin toxicity. Concurrent use should be carefully monitored.
- Mild to moderate renal impairment: If you have mild or moderate kidney disease, you can usually still receive teriparatide, but your doctor will monitor kidney function and serum/urinary calcium more closely.
- Hepatic impairment: No dose adjustment is required for liver impairment, but data in patients with severe liver disease are limited.
- Vitamin D and calcium status: Vitamin D deficiency or dietary calcium insufficiency should be corrected before starting therapy. Patients are usually advised to take supplemental calcium (approximately 1000 mg/day) and vitamin D (400–800 IU/day) unless their dietary intake is already adequate.
Your doctor will schedule periodic check-ups during treatment to monitor your response, check serum calcium (occasionally, if indicated), evaluate blood pressure, and assess tolerability. Fragility fractures and significant changes in height should be reported promptly.
Pregnancy and Breastfeeding
Teriparatide Ambio Pharma must not be used during pregnancy. Although limited human data are available, animal studies have shown developmental toxicity, and the safety of teriparatide in pregnant women has not been established. Women of childbearing potential should use effective contraception during treatment. If you become pregnant while using teriparatide, stop treatment immediately and contact your doctor.
Teriparatide is also contraindicated during breastfeeding. It is not known whether teriparatide is excreted in human breast milk, and a risk to the nursing infant cannot be excluded. Mothers who wish to breastfeed should discuss alternative osteoporosis therapies with their doctor.
Children and Adolescents
Teriparatide Ambio Pharma is not indicated in children and adolescents (below 18 years of age) or in young adults with open epiphyses (growth plates). Because preclinical studies in growing rats demonstrated an increased incidence of osteosarcoma, exposure during skeletal growth is considered an absolute contraindication. The medicine is also not approved for the treatment of juvenile osteoporosis or osteogenesis imperfecta outside of clinical trials.
Driving and Using Machines
Teriparatide has no or negligible influence on the ability to drive and use machines in most patients. However, transient dizziness and orthostatic hypotension – most likely after the first few doses – may affect driving ability. If you feel dizzy after an injection, wait until symptoms resolve before driving or operating potentially dangerous machinery.
How Does Teriparatide Ambio Pharma Interact with Other Drugs?
Because teriparatide is a peptide hormone, it is degraded by non-specific proteases in the liver and other tissues, not by cytochrome P450 enzymes. This means that the majority of common drug interactions seen with small-molecule medicines (for example, those mediated by CYP3A4 induction or inhibition) do not apply. The main concerns relate to its effects on calcium homeostasis and bone metabolism.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Digoxin | Transient rises in serum calcium may increase the risk of digoxin toxicity and cardiac arrhythmias | Use with caution; clinical monitoring required. Not an absolute contraindication, but avoid combination where possible. |
| Calcium supplements | Additive effect on serum calcium; theoretical risk of hypercalcemia | Recommended supplementation is still required (typically 1000 mg/day). Very high-dose supplementation should be avoided unless specifically directed. |
| Vitamin D analogs (including calcitriol, alfacalcidol) | Additive effect on calcium absorption and serum calcium | Maintain standard replacement doses (400–800 IU/day) unless specifically directed. Higher doses may require monitoring. |
| Thiazide diuretics (e.g., hydrochlorothiazide, bendroflumethiazide) | Reduced urinary calcium excretion, increased risk of hypercalcemia | Monitor serum calcium; dose adjustment of diuretic may be considered in some patients. |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Bisphosphonates (alendronate, risedronate, zoledronate) | Concurrent use may blunt the anabolic response to teriparatide in some studies; sequential therapy is preferred | Bisphosphonates are usually given after completion of teriparatide to preserve gains rather than concurrently. |
| Denosumab | Combined use (“DATA” regimen) increases bone density more than either drug alone in clinical studies | Occasionally used in severe osteoporosis under specialist supervision; not a standard approach. |
| Systemic glucocorticoids (prednisone, dexamethasone) | Steroids antagonize bone formation; teriparatide is specifically approved for glucocorticoid-induced osteoporosis | Concomitant use is expected and appropriate in glucocorticoid-treated patients at high fracture risk. |
| Proton pump inhibitors / H2 blockers | May slightly reduce calcium absorption; no direct interaction with teriparatide | Ensure adequate calcium and vitamin D intake; usually no dose adjustment needed. |
| Loop diuretics (furosemide) | Increased urinary calcium loss may partially offset calcium-raising effect of teriparatide | Monitor calcium status; dose adjustment not typically needed. |
Tell your doctor about all medicines you are taking, including over-the-counter products, vitamins, and herbal supplements, before starting Teriparatide Ambio Pharma. Your doctor will consider the overall medication plan to ensure it is appropriate for anabolic therapy.
What Is the Correct Dosage of Teriparatide Ambio Pharma?
Teriparatide Ambio Pharma is supplied as a 20 microgram in 80 microliter solution in a disposable pre-filled pen designed to deliver 28 daily doses. The dosing regimen is identical for all approved indications, and the pen simplifies administration by offering a fixed dose and visual injection guidance. Patients or their carers should be trained in pen handling, injection technique, and disposal by a qualified healthcare professional before starting self-injection.
Adults
Standard Dose (All Approved Indications)
Dose: 20 micrograms once daily
Route: Subcutaneous injection into the thigh or abdomen
Time of day: At approximately the same time each day, whenever is most convenient. It can be taken with or without food.
Maximum lifetime duration: 24 months (cumulative)
Supplemental calcium (around 1000 mg/day) and vitamin D (400–800 IU/day) should usually be taken unless dietary intake is already sufficient.
Elderly Patients
No dose adjustment is required for older adults. Teriparatide is commonly used in patients aged 70 years and older, including the very elderly (over 80 years), who have a particularly high fracture risk. Cognitive ability to handle the injection pen should be assessed, and if necessary a carer or community nurse can be trained to assist with daily administration.
Patients with Kidney Impairment
- Mild renal impairment (creatinine clearance 50–80 mL/min): No dose adjustment required.
- Moderate renal impairment (creatinine clearance 30–49 mL/min): Use with caution; no formal dose reduction is recommended, but monitoring of serum calcium and renal function is advised.
- Severe renal impairment (creatinine clearance below 30 mL/min): Teriparatide is contraindicated.
Patients with Liver Impairment
No dose adjustment is required in patients with mild or moderate hepatic impairment. Data in severe liver disease are limited, so teriparatide should be used with caution in this group.
Children and Adolescents
Teriparatide Ambio Pharma is not recommended for use in children and adolescents under 18 years of age or in young adults with open epiphyses. This restriction is based on preclinical safety data and the theoretical risk of osteosarcoma in the growing skeleton.
Missed Dose
If you miss an injection, you should inject it as soon as you remember on the same day. Do not inject two doses on the same day to make up for a missed dose, and never inject more than one dose in any 24-hour period. The following day, continue at your usual time. Missing an occasional dose is unlikely to affect overall efficacy, but routine adherence is important for the bone-building effect.
Overdose
Accidental overdose with teriparatide has been reported rarely, mainly due to pen misuse. Expected symptoms would include nausea, vomiting, dizziness, headache, and orthostatic hypotension. Serum calcium may rise transiently, typically peaking 4–6 hours after injection and returning toward baseline within 16–24 hours.
There is no specific antidote. Management is supportive and includes rest, adequate hydration, and measurement of serum calcium if symptoms are marked. In the rare case of significant hypercalcemia, intravenous fluids and symptomatic treatment may be needed. If a significant overdose is suspected, contact your doctor or nearest emergency department immediately, and bring the pen and packaging with you.
How Teriparatide Ambio Pharma Is Given
The pre-filled pen is used to deliver a fixed 20 microgram daily dose via a short, fine needle. Needles are not included with every pen and should be obtained from your pharmacist. A new, sterile needle must be used for every injection.
General step-by-step guidance (always follow the manufacturer’s Instructions for Use):
- Remove the pen from the refrigerator. Check the solution is clear and colorless; do not use if cloudy, discolored, or containing particles.
- Wash your hands.
- Attach a new needle and remove the outer and inner needle caps.
- Dial or confirm the 20 microgram dose as described in the Instructions for Use.
- Clean a small area of skin on the thigh or lower abdomen with an alcohol swab.
- Pinch a fold of skin, insert the needle at 90 degrees, and press the injection button fully until the dose counter returns to zero.
- Hold the needle under the skin for 5–10 seconds to ensure full dose delivery.
- Withdraw the needle, replace the outer cap safely, and dispose of the needle in an approved sharps container.
- Return the pen to the refrigerator.
Rotate the injection site (alternate between thighs, or between thigh and abdomen) to reduce the risk of local skin reactions. After 28 injections, or when the marked expiry label is reached (whichever comes first), the pen should be discarded and a new one started.
What Are the Side Effects of Teriparatide Ambio Pharma?
Like all medicines, Teriparatide Ambio Pharma can cause side effects, though not everyone gets them. The side effects listed below are grouped by frequency, using standard MedDRA categories, and reflect pooled data from pivotal trials of the reference medicine and post-marketing experience with teriparatide. Most side effects are mild to moderate and often resolve during the first weeks of treatment.
Side Effect Frequency
Very Common
May affect more than 1 in 10 people
- Pain in the limbs (arms or legs)
- Nausea
- Headache
- Dizziness
- Joint pain (arthralgia)
Common
May affect up to 1 in 10 people
- Palpitations (awareness of the heartbeat)
- Shortness of breath
- Gastrointestinal reflux (heartburn, indigestion)
- Vomiting
- Hiatus hernia
- Increased sweating
- Muscle cramps
- Fatigue or asthenia (weakness)
- Chest pain (non-cardiac)
- Anemia
- Increased blood cholesterol
- Depression
- Vertigo
- Sciatica
- Tinnitus (ringing in the ears)
- Venous swelling at injection site (mild)
Uncommon
May affect up to 1 in 100 people
- Increased heart rate (tachycardia)
- Hypercalcemia greater than 2.76 mmol/L
- Abnormal taste (dysgeusia)
- Weight gain
- Heart murmur
- Elevated alkaline phosphatase
- Hemorrhoids
- Incontinence of urine
- Kidney stones (nephrolithiasis, urolithiasis)
- Urinary frequency or polyuria
- Injection-site reactions (pain, redness, swelling, bruising, itching, minor bleeding)
Rare
May affect up to 1 in 1,000 people
- Impaired kidney function, including acute kidney failure
- Angioedema (swelling of the face, throat or tongue)
- Urticaria (hives)
- Anaphylactic reaction
- Hypercalcemia greater than 3.25 mmol/L
Not Known
Frequency cannot be estimated from available data
- Severe localized reactions at the injection site in patients sensitive to metacresol (preservative)
- Muscle spasms of the back or extremities reported shortly after injection
- Allergic reactions that occurred soon after injection: acute dyspnea, oro/facial oedema, generalized urticaria, chest pain, oedema (mainly peripheral)
Infusion and Post-Injection Reactions
Transient symptoms after injection – including light-headedness, feeling faint, nausea, palpitations, or flushing – are most common during the first few doses and usually abate with continued use. If you experience significant orthostatic hypotension, it may help to sit or lie down for a few minutes after each injection. True hypersensitivity reactions are rare but can occur and may include hives, facial swelling, breathing difficulties, or anaphylaxis. Stop injecting and seek emergency care if you develop any such symptoms.
If you experience any side effects, including those not listed here, tell your doctor, pharmacist, or nurse. You can also report suspected side effects directly to your national pharmacovigilance authority, such as the EMA EudraVigilance system (EU), the FDA MedWatch program (US), the MHRA Yellow Card Scheme (UK), or the WHO Uppsala Monitoring Centre. Reporting side effects helps provide more information on the safety of medicines.
How Should Teriparatide Ambio Pharma Be Stored?
Proper storage is essential to preserve the biological activity of teriparatide. As a peptide medicine, it is sensitive to heat, freezing, and light. Follow these rules carefully:
- Temperature: Always store the pen in a refrigerator between 2 °C and 8 °C (36 °F to 46 °F), both before and after first use.
- Do not freeze: If a pen has been frozen, it must not be used, even if it appears unchanged. Freezing damages the protein structure.
- Protection from light: Keep the pen in its outer carton when not in use.
- Keep the cap on the pen: Store the pen with the cap in place to protect it from light and physical damage.
- After first injection: The pen can be used for a maximum of 28 days from the first injection. Write the date of first use on the carton to help you track this. After 28 days, discard any remaining medicine even if doses are left.
- Do not store the pen with a needle attached: This prevents contamination, leakage, and premature clogging of the needle. Remove and safely discard the needle after every injection.
- Short-term removal from the refrigerator: Brief periods (typically up to a few hours) out of the refrigerator during transport are acceptable as long as the temperature stays below 25 °C, but prolonged exposure to room temperature should be avoided.
- Keep out of reach of children: Always store medicines safely away from children, both in the refrigerator and during travel.
- Expiry date: Do not use after the expiry date (EXP) printed on the pen and outer carton. The expiry date refers to the last day of that month.
Do not dispose of any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. Used needles should always go into a puncture-proof sharps container, which is returned to the pharmacy or disposed of according to local regulations.
What Does Teriparatide Ambio Pharma Contain?
Active Substance
The active substance is teriparatide. Each dose of 80 microliters contains 20 micrograms of teriparatide. Each pre-filled pen contains 2.4 mL of solution, corresponding to 600 micrograms of teriparatide, which is sufficient for 28 daily doses.
Teriparatide is a recombinant protein comprising the first 34 amino acids of human parathyroid hormone. Its amino-acid sequence is: Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe. It has a molecular mass of approximately 4118 daltons.
Inactive Ingredients (Excipients)
- Glacial acetic acid
- Sodium acetate trihydrate
- Mannitol (E421)
- Metacresol (preservative)
- Water for injections
- Hydrochloric acid (for pH adjustment)
- Sodium hydroxide (for pH adjustment)
Appearance and Pack Size
Teriparatide Ambio Pharma is a clear, colorless solution for injection supplied in a glass cartridge that is sealed within a disposable multi-dose pre-filled pen. The pen is typically supplied as a single pen per carton, providing 28 days of therapy at the standard dose of 20 micrograms once daily.
Sodium Content
This medicine contains less than 1 mmol sodium (23 mg) per dose and is therefore considered essentially “sodium-free”. It is suitable for patients on a controlled-sodium diet.
Marketing Authorization Holder and Manufacturer
Teriparatide Ambio Pharma is manufactured and distributed by Ambio Pharma. For specific distributor information in your country, consult the local Summary of Product Characteristics (SmPC) or package leaflet. The reference medicine (Forsteo/Forteo) is manufactured by Eli Lilly.
Frequently Asked Questions About Teriparatide Ambio Pharma
Teriparatide Ambio Pharma is used to treat severe osteoporosis in adults at high risk of fracture. It is approved for postmenopausal women and men with osteoporosis at increased fracture risk, and for osteoporosis associated with sustained systemic glucocorticoid (steroid) therapy. Unlike antiresorptive drugs, it is an anabolic (bone-building) medicine that increases bone mineral density and significantly reduces the risk of new vertebral and non-vertebral fractures.
Teriparatide Ambio Pharma is given as a once-daily subcutaneous injection using a pre-filled pen. The usual injection sites are the thigh or lower abdomen. After cleaning the area, you attach a new needle to the pen, confirm the 20 microgram dose, pinch the skin, insert the needle at 90 degrees, and press the injection button. Hold the needle under the skin for 5–10 seconds to deliver the full dose, then safely dispose of the needle. Your healthcare team will train you before you start self-injecting.
The maximum lifetime duration of teriparatide therapy is 24 months. This limit is based on long-term animal studies that showed an increased incidence of osteosarcoma (bone cancer) with very high-dose, long-duration exposure in growing rats. Although no causal link has been established in humans, the 24-month cap is a precautionary measure. After completing teriparatide, most patients are transitioned to an antiresorptive drug such as a bisphosphonate or denosumab to preserve the bone density gains. Teriparatide is not repeated after the 24-month course.
Yes. Teriparatide Ambio Pharma is a biosimilar to Forsteo/Forteo, the reference teriparatide medicine first authorized by Eli Lilly. Biosimilars are biological medicines that are approved only after they have been shown through comparative studies to be highly similar to their reference product in terms of structure, efficacy, safety, and immunogenicity. They are not the same as generic versions of small-molecule drugs, because biologicals are too complex to be exactly copied. Biosimilars offer the same clinical benefits at a generally lower cost.
In young, growing rats given high doses of teriparatide for most of their lifetime, there was a dose-dependent increase in osteosarcoma. However, extensive post-marketing surveillance in humans – involving more than 20 years of clinical use and registry data – has not demonstrated a causal link between teriparatide and osteosarcoma. Nevertheless, as a precaution, teriparatide is contraindicated in people at increased baseline risk of osteosarcoma (Paget’s disease, unexplained elevations of alkaline phosphatase, open growth plates, and prior skeletal radiation), and the lifetime treatment duration is capped at 24 months.
When teriparatide is stopped, the bone mineral density gains can be lost within 1–2 years unless follow-on therapy is given. For this reason, most guidelines recommend that teriparatide is followed by an antiresorptive medicine – most commonly a bisphosphonate (such as alendronate, risedronate, or zoledronate) or denosumab – to lock in the benefits. Your specialist will plan the transition in advance and will arrange bone-density monitoring after completion to confirm preservation of gains.
The pivotal Fracture Prevention Trial showed that teriparatide 20 micrograms daily for a median of 19 months reduced the risk of new vertebral fractures by approximately 65% and of non-vertebral fragility fractures by about 53% in postmenopausal women with severe osteoporosis. Head-to-head studies in glucocorticoid-induced osteoporosis (the EuroGIOPS trial) and real-world cohorts such as the European Forsteo Observational Study (EFOS) have consistently confirmed large reductions in fracture rates, improvements in back pain, and sustained benefits when patients transition to antiresorptive maintenance therapy.
References
- European Medicines Agency (EMA). Forsteo (teriparatide) – Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR.
- U.S. Food and Drug Administration (FDA). Forteo (teriparatide) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi:10.1056/NEJM200105103441904.
- Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–3355. doi:10.1002/art.24879.
- Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO). Lancet. 2018;391(10117):230–240. doi:10.1016/S0140-6736(17)32137-2.
- Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis. Osteoporos Int. 2005;16(5):510–516.
- Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2024;35(1):1–48.
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists / American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. Endocr Pract. 2020;26(Suppl 1):1–46.
- World Health Organization (WHO). Prevention and management of osteoporosis. WHO Technical Report Series 921. Geneva: WHO.
- Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy (STRUCTURE). Lancet. 2017;390(10102):1585–1594.
- Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study). Lancet. 2015;386(9999):1147–1155.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in endocrinology, metabolic bone disease, rheumatology, and clinical pharmacology.
Medical Content
iMedic Endocrinology Editorial Team – specialist physicians in metabolic bone disease and osteoporosis management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, IOF-ESCEO, and AACE/ACE guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, biosimilar assessment, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.